⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 2, 2025Open Access

Supplementary Figure 5 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Kaushik Varadarajan Christian X. Cruz Pico Kurt W. Evans Maria Gabriela Raso Yasmeen Q. Rizvi Xiaofeng Zheng Dhruv Chachad Timothy P. DiPeri Bailiang Wang Stephen M. Scott Ming Zhao Argun Akçakanat Antje M. Wengner Timothy A. Yap Funda Meric‐Bernstam

View Full Paper

Ask AI

Bookmark

Share

Key Points

Tolerability of 40 mg/kg elimusertib was analyzed in tumors, demonstrating its acceptable profile.
The results indicate that the ATR kinase inhibitor can be combined with other therapies to enhance effects.
The analysis focused on tumors with genomic alterations, revealing significant insights into treatment outcomes.
The findings support further exploration of deducing therapy strategies in oncology using this intervention.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Supplementary figure reports tolerability of 40 mg/kg elimusertib in tumors with DNA damage response, suggesting potential for broader applications.

Abstract

Supplementary Figure 5: Tolerability of 40 mg/kg elimusertib

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Varadarajan et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02875 https://doi.org/10.1158/1535-7163.30028663

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
2Supplementary Figure 3 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
3Supplementary Figure 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
4Supplementary Figure 10 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025
5Supplementary Figure 6 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations2025